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percutaneous stereotactic image-
guided microwave ablation for 
malignant liver lesions
Stéphanie perrodin1, Anja Lachenmayer1, Martin Maurer2, corina Kim-fuchs1, 
Daniel candinas1 & Vanessa Banz1
Thermal ablation has proven beneficial for hepatocellular carcinoma and possibly for colorectal 
liver metastases, but data is lacking for other liver metastases. computer-assisted navigation can 
increase ablation efficacy and broaden its indications. We present our experience with percutaneous 
stereotactic image-guided microwave ablation (SMWA) for non-colorectal liver metastases (NCRLM), 
in form of a retrospective study including all SMWA for NCRLM from 2015 to 2017. Indication for SMWA 
was determined at a multidisciplinary tumorboard. end-points include recurrence, overall and liver-
specific disease progression and complications. Twenty-three patients underwent 25 interventions 
for 40 lesions, including 17 neuroendocrine tumor, nine breast cancer, four sarcoma, two non-small 
cell lung cancer, three duodenal adenocarcinoma, one esophageal adenocarcinoma, one pancreatic 
adenocarcinoma, one ampullary carcinoma, one prostate carcinoma, and one renal cell carcinoma 
metastases. Median follow-up was 15 months (2–32). Incomplete ablation rate was 2.5% (1/40), local 
recurrence rate 10% (4/40). Three patients (12%) had minor complications. Overall disease progression 
was 73.9% (17/23), median disease-free survival 7 months (0–26) and overall survival 18 months (2–39). 
SIMWA is feasible, safe and minimally invasive for NCRLM in selected patients. While it might offer an 
alternative to resection or palliative strategies, the oncological benefit needs to be evaluated in a larger 
patient cohort.
Ablation is an increasingly recognized alternative to surgery for liver tumors in patients with impaired liver func-
tion, associated extrahepatic disease, lesions inaccessible to surgical resection, extensive bilobar metastatic disease 
or concurrent medical conditions precluding an operation1.
Thermal Ablation techniques include radiofrequency ablation (RFA) and microwave ablation (MWA). The 
advantages of MWA are the potential to treat larger tumors faster, with a reduced perivascular heat sink effect2. 
MWA is well recognized for hepatocellular carcinoma (HCC), where it has been shown to be a safe, effective 
and minimally-invasive treatment option, that can be repeated in case of local recurrence3. It is also increasingly 
recognized for colorectal liver metastases (CRLM), where it is being investigated in the setting of prospective 
randomized clinical trials, comparing surgery to thermal ablation, such as the COLLISION Trial4–7.
Furthermore, the use of MWA for the treatment of other liver metastases with curative intent, such as is 
the case for hepatic neuroendocrine tumor (NET) metastases, is gaining popularity. When feasible, treatment 
with curative intent for hepatic NET metastases consists in (if necessary, repeated) liver resection, resulting 
in improved survival8–10. However, while current data show that RFA of NET liver metastases may be benefi-
cial, there is still no conclusive evidence on the efficacy of MWA for such lesions11. Data is even scarcer on the 
treatment of other hepatic tumor entities using MWA and the benefit of such local treatment strategies remains 
unproven.
More recently, image-guided ablation is increasingly being combined with computer-assisted stereotactic 
navigation12. Computer-assisted stereotactic navigation is particularly interesting in the setting of very small 
or invisible “vanishing” lesions (targeting accuracy), very large lesions requiring multiple needle placements in 
order to achieve complete ablation, or difficult-to-reach or treat lesions (close proximity to major vessels/bile 
ducts, liver dome, segment I lesions). The use of computer-assisted stereotactic navigation has shown to improve 
the precision of the needle placement13–15, but data is lacking on complete ablation rates and long-term results.
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The aim of our study is to analyze our cohort of patients with liver metastasis of non-colorectal, non-HCC 
origin treated with stereotactic image-guided microwave ablation (SMWA) between 2015 and 2017.
Methods
Between January 2015 and December 2017, 163 patients with 286 lesions were treated with SMWA in our institu-
tion, a certified cancer center. Most patients had HCC or CRLM. We performed a retrospective analysis of prospec-
tively collected data from all patients undergoing SMWA for liver metastases of non-colorectal, non-HCC origin in 
this time period. SMWA was carried out as per recommendation by our multidisciplinary tumorboard. Obligatory 
participants include a radiologist, an interventional radiologist, a hepatologist, an oncologist, a radiooncologist, a 
pathologist and a hepatobiliary surgeon. Exclusion criteria were cross-sectional images (CT or MRI) indicative for, 
or biopsy proven HCC, CRLM or benign lesions. Clinical data was obtained from the electronic patient files.
End-points included local recurrence rate at the site of ablation, appearance of new intrahepatic or extrahepatic 
lesions, post-interventional complications according to the Clavien-Dindo Classification16 and hospital length of stay.
Follow-up consisted of 3-monthly clinical and radiological (CT scan or MRI) check-ups. Additional oncolog-
ical follow-up was carried out at the discretion of and as recommended by the treating oncologist.
Incomplete ablation was defined as detectable tumor on the edge of the ablation zone on the first post-SMWA 
follow-up image. An initial imaging is carried out directly post-ablation while the patient is still in the CT suite, 
allowing for immediate validation of treatment efficacy. Local recurrence was defined as the presence of a detect-
able tumor within 10 mm from the edge of the ablation zone17.
The study protocol was approved by the Regional Ethical Review Boards in Bern (Kantonale Ethikkommission 
Bern, KEK-Nr. 2017-01038). General consent was obtained at time of hospitalisation, but specific consent was 
waived due to the retrospective study design. The study was performed in accordance with the relevant national 
guidelines and regulations.
Stereotactic image-ablation. All CT-guided interventions were performed by a dedicated interdiscipli-
nary team of surgeons and radiologists, based on CT imaging. Trajectory planning, probe positioning and vali-
dation of treatment was conducted using a commercially available navigation system for interventional radiology 
(CAS-ONE, CASination AG, Bern, Switzerland). Microwave energy (Acculis MTA System, AngioDynamics, 
Latham, NY, USA) was used.
Interventions were performed under general anesthesia, and patients were ventilated using high frequency jet 
ventilation, ensuring minimal diaphragmatic movement during the procedure.
The procedure included the following steps: Planning of the trajectory of the ablation needle, navigated posi-
tioning of the ablation needles in the lesion, validation of their localisation in the liver and ablation of the lesion 
using 100 W energy. The duration of ablation was determined according to the size of the lesion, the proximity to 
blood vessels or bile ducts and the quality of the surrounding liver tissue. Finally, the pre- and post-ablation CT 
scans were overlayed to validate the ablation zone.
Statistical analysis. Descriptive statistics were used to present patient characteristics and results. 
Continuous data is presented as total number, percentage, mean and standard deviation or median and range. All 
analyses were performed using a commercially available software (SPSS version 25).
Results
patient characteristics. In total, 23 patients required 25 interventions to treat 40 malignant liver lesions of 
non-colorectal, non-HCC origin.
Most patients were male, median age was 61 years and 74% of patients presented with significant comorbidi-
ties, ASA III or more (Table 1)18.
In 87% of patients the liver metastases were diagnosed 3 to 312 months after initial diagnosis of the primary 
tumor. In two patients the liver metastases and the primary tumor were diagnosed at the same time. In one 
patient the liver metastasis was diagnosed prior to identification of the primary tumor. Five patients underwent 
previous local treatment for liver metastases, such as laparoscopic MWA or surgical resection. Three patients had 
stable extrahepatic disease at the time of SMWA, and almost one third of patients underwent SMWA while under 
systemic therapy.
Eight patients had liver metastases originating from a NET, four from breast cancer, three from a sarcoma, two from 
a non-small cell lung cancer (NSCLC), and one each from a duodenal adenocarcinoma, esophageal adenocarcinoma, 
pancreatic adenocarcinoma, renal clear cell carcinoma, ampullary carcinoma and prostate carcinoma (Fig. 1).
The decision to use SMWA was always based on the multidisciplinary tumorboard recommendation. A 
detailed description can be found in Table 2.
intervention data. Most patients underwent one SMWA session; two underwent a second SMWA session, 
one to treat an incomplete ablation and two new liver lesions, the other to treat a single new liver lesion. In 74% of 
patients (n = 17), a CT-guided biopsy of the lesion was performed during SMWA, proving the diagnosis in all but 
two patients, where histology was inconclusive. The smallest successfully biopsied lesion was 7 mm in diameter 
in this series. One to four lesions were treated per session, with all lesions being smaller than four centimeters in 
diameter (Table 3). One patient presented with incomplete ablation as diagnosed on the first post-SMWA imaging 
immediately after the intervention, and confirmed on the follow-up imaging at 3 months. The lesion had to be 
treated with special care initially, as it was in segment I and close to the vena cava, where the heat sink effect was 
higher. We successfully treated this incomplete ablation with an irreversible electroporation (IRE) session.
Lesion location did not limit treatment option, with any location within the liver amenable to SMWA. The 
majority of lesions were located at the liver dome (Segment VII and VIII) and in segment IV, two lesions were 
treated in segment I (Fig. 2).
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post-interventional data. Length of hospital stay was two nights for the majority of patients (Table 4). There 
were no major complications. Three (12%) patients presented with minor complications (≤grade IIIa), including 
one pleuritis (grade I), one liver abscess requiring rehospitalisation and percutaneous drainage (grade IIIa), and one 
thrombosis of a branch of the left portal vein necessitating anticoagulation for three months (grade II).
Median follow-up was 15 months (2–32). We observed local recurrence in four patients, diagnosed on the 
first follow-up scan at three months. All four patients also presented with disease progression – intra- and/or 
extrahepatic - prompting a change in therapeutic strategy, so that no re-ablation was attempted. Overall disease 
progression was observed in 74% of patients (n = 17), at a median of seven months after SMWA (range 0–25). 
Isolated intrahepatic disease progression occurred in five patients.
Seven patients died of disease progression during the follow-up period, between 2 and 25 months after 
SMWA. The patient who died two months after SMWA had NSCLC, and cerebral metastases were diagnosed 
shortly after the intervention.
Discussion
In this study, we are able to demonstrate that stereotactic ablation is a very safe and technically feasible treatment 
for patients with malignant liver lesions. Using a navigated, percutaneous approach not only allows for the treat-
ment of lesions otherwise not amenable to ablation (such as lesions located close to major vessels and bile ducts, 
subcapsular, subdiaphragmatic liver dome lesions, or lesion located in segment I). It also allows for simultaneous, 
diagnostic biopsy of very small (sub-centimetric) tumors within the liver. Being able to precisely biopsy and 
simultaneously ablate very small lesions is of particular interest in a patient population with a history of previous 
cancer or in the setting of concomitant tumors, where determining the origin of the liver metastases at a very 
Variable
Mean age, years (range) 58.4 (7–79)
Male gender, n (%) 13 (56.5)
ASA classification, n (%)
  ASA II 6 (26.1)
  ASA III 16 (69.6)
  ASA IV 1 (4.3)
Identification of liver metastases, n (%)
  Before primary tumor 1 (4.3)
  At the same time 2 (8.7)
  After primary tumor 20 (87)
Median time between initial diagnosis and metastasis, months (range) 19 (0–312)
Previous treatment for liver metastases, n (%) 5 (21.7)
  IRE 1 (4.3)
  Surgical resection only 2 (8.7)
  Surgical resection and open MWA 1 (4.3)
  Laparoscopic MWA 1 (4.3)
Extra-hepatic disease at time of SMWA, n (%) 3 (13)
Systemic therapy at time of SMWA, n (%) 7 (30.4)
Table 1. Patients characteristics (n = 23). ASA American Society for Anesthesia, IRE irreversible 
electroporation, MWA Microwaveablation.
Figure 1. Origin and number of treated liver metastases. NET Neuroendocrine Tumor, NSCLC Non-small cell 
lung cancer.
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Patient Tumor entity
Treatment before 
SMWA Tumorboard decision
Systemic 
treatment at 
time of SMWA
Follow-up 
time,
months
Number 
of sessions
Number 
of treated 
lesions
Incomplete 
ablation
Local 
recurrence
Disease 
progression 
in the liver
Disease 
progression 
elsewhere
1 NET
Resection 
of primary 
tumor, systemic 
Sandostatin
Ablation by adverse 
reaction to sandostatin 
treatment
none 14 1 1
2 NET
Resection 
of primary 
tumor, systemic 
Sandostatin
Only two lesions, 
minimal progression 
under systemic therapy
Sandostatin 17 1 2 X
3 NET
Resection of 
primary tumor 
and Laparoscopic 
MWA
Single lesion on two 
separate occasions none 18 1 1
4 NET Resection of primary tumor
Two clearly defined 
metastasis none 24 1 2
5 NET
Resection 
of primary 
tumor, systemic 
Sandostatin
Multiple liver 
metastasis, ablation 
of the biggest lesions 
(debulking)
Sandostatin 19 1 4 X
6 NET Resection of primary tumor
Single metastasis in 
segment I, operative 
risk too high
none 20 2 4 X X
7 NET
Metabolic therapy, 
resection primary 
tumor
Multiple liver 
metastasis, after 
systemic therapy only 
one remains
none 22 1 1 X
8 NET Resection of primary tumor
To confirm diagnosis, 
biopsy and ablation of 
single lesion
none 10 1 1 X X
9 Breast cancer,Triple-positive
Resection of 
primary tumor, 
radiotherapy, 
hormonal therapy
Single liver metastasis, 
biopsy indicated 
by previous rectum 
carcinoma, ablation in 
the same session
hormonal 
therapy 29 1 2 X X
10
Breast cancer,
ER and HER-2 
positive
Resection 
of primary 
tumor, adjuvant 
chemotherapy, 
immunotherapy 
and radiotherapy
Two liver metastasis, 
good response under 
systemic therapy
immunotherapy 15 1 2 X
11 Breast cancer,HER-2 positive
Resection 
of primary 
tumor, adjuvant 
chemotherapy and 
immunotherapy
Two vanishing liver 
metastasis, biopsy and 
ablation indicated
adjuvant 
chemotherapy 
and 
immunotherapy
14 1 1
12 Breast cancer, triple-negative
Resection of 
primary tumor, 
palliative 
chemotherapy
Single liver metastasis, 
young patient. 2nd 
ablation under 
chemotherapy, patient 
wishes
chemotherapy 22 2 4 X X
13 Sarcoma
Resection of 
primary tumor, 
hemihepatectomy 
and MWA for two 
lesions in the left 
liver
No other metastasis, 
young patient, limited 
therapeutic options
none 10 1 4 X
14 Sarcoma Resection of primary tumor
Ablation for single 
growing liver 
metastasis, with stable 
small pulmonary 
lesions
none 22 1 1 X
15 Sarcoma Resection of primary tumor
Single liver lesion, 
biopsy indicated, 
concomitant ablation
none 17 1 1 X X
16 NSCLC Resection of primary tumor
Single liver 
lesion, biopsy and 
concomitant ablation 
indicated by DD HCC
none 2 1 1 X
17 NSCLC
Resection 
of primary 
tumor, adjuvant 
chemotherapy, 
Radiosurgery brain 
metastasis
Long oligometastatic 
course, systemic 
therapy contra-
indicated, ablation for 
single lesion
none 7 1 1 X X
Continued
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early stage is a prerequisite for correct and rapid diagnosis and treatment. This concurs with currently available 
literature reports, which show that the use of a navigation system improves precision of needle placement and 
reduces multiple needle repositioning12–14.
Patient Tumor entity
Treatment before 
SMWA Tumorboard decision
Systemic 
treatment at 
time of SMWA
Follow-up 
time,
months
Number 
of sessions
Number 
of treated 
lesions
Incomplete 
ablation
Local 
recurrence
Disease 
progression 
in the liver
Disease 
progression 
elsewhere
18 Duodenum adenocarcinoma
Resection 
of primary 
tumor, adjuvant 
chemotherapy, 
palliative 
chemotherapy for 
local recurrence
Three isolated liver 
metastasis two 
years after end of 
chemotherapy, young 
patient
none 10 1 3 X X X
19 Esophagus adenocarcinoma
Palliative 
chemotherapy 
(liver metastasis 
diagnosed before 
primary tumor)
Liver cirrhosis, liver 
lesion suspicious of 
HCC, biopsy and 
concomitant ablation 
indicated
none 7 1 1 X X X
20 Pancreas adenocarcinoma
Palliative 
chemotherapy and 
radiotherapy
single lesion, atypical 
for metastasis 
from pancreatic 
adenocarcinoma, 
biopsy indicated, 
ablation at the same 
time
none 7 1 1
21 Renal clear cell carcinoma
Resection of 
primary tumor
Single liver lesion, 
biopsy indicated, and 
concomitant ablation
none 20 1 1
22 Prostatic carcinoma
Resection of 
primary tumor, 
antiresorbtive 
and antiandrogen 
therapy
Single metastasis, 
origin unclear by 
previous rectal 
carcinoma, biopsy and 
ablation indicated
antiresorbtive 
and 
antiandrogen 
therapy
8 1 1 X
23 Ampullary carcinoma
Resection 
of primary 
tumor, adjuvant 
chemotherapy
Single metastasis, 
stable months after end 
of chemotherapy
none 6 1 1 X X
Table 2. Detailed results per patient. MWA Microwave ablation, DD differential diagnosis, HCC Hepatocellular 
carcinoma.
Figure 2. Distribution of treated liver lesions, per segment.
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SMWA can be safely performed in patients while under systemic therapy, without additional risks and without 
the need to stop the therapy. In this setting, SMWA may be seen as an adjunct to a systemic therapy or other local 
treatment strategies.
In contrast to more invasive local treatment options such as surgical tumor resection, SMWA is tolerated 
very well, with the vast majority of patients not suffering from any postoperative symptoms or complications, 
and a short hospital-stay. Postinterventional intrahepatic thrombosis have been reported in patients treated by 
thermal ablation close to a blood vessel19–21, and portal veins are particularly susceptible to thrombosis21, which 
could have serious consequences in patients with little hepatic reserve, due to underlying liver disease or previous 
interventions. Following this complication, we elected to treat all patients with prophylactic anticoagulation if 
the ablation had been performed close to a major blood vessel. One patient with a hepaticojejunostomy after a 
pancreaticoduodenectomy presented with an abscess in the ablation zone and was treated with antibiotics. This 
population has been identified as at higher risk for post-ablation abscesses22,23. Following this, we implemented 
a prophylactic antibiotic regimen in all patients undergoing SMWA. No further abscesses were seen. Further 
studies are needed to determine if this is necessary, or if prophylactic antibiotics should be reserved for high-risk 
patients. Other common complications include injury to the biliary tract, pleural effusion and liver dysfunction, 
which did not occur in this series24,25. Whether or not this can be attributed to the use of navigation technology 
needs to be further analyzed.
Cancer treatment is becoming increasingly personalized. In selected patients with oligometastatic disease 
in whom the classical systemic therapies fail to offer complete tumor response, SMWA may be an alternative 
treatment for local tumor control of single active tumor lesions. SMWA also allows for simultaneous acquisition 
of tissue for histopathological and molecular analyses, in particular in the context of now increasingly available 
tumor-targeted treatments26.
However, in our patient cohort, ultimately 3/4 of patients presented with some form of disease progression in 
the shorter or longer term. This stresses the importance of patient selection, so that the indication for SMWA or 
any other local treatment for hepatic metastases has to be made in the setting of a multidisciplinary tumorboard. 
Variable
Number of treated lesions, n 40
SMWA sessions, n 25
Median number of session per patient, n (range) 1 (1–2)
Median number of treated lesions per session, n (range) 2 (1–4)
Median lesion size, mm (range) 13.5 (6–39)
Median duration of ablation, minutes (range) 4.75 (1.25–18)
Intraoperative biopsy, n (%) 17 (73.9)
Positive biopsy 15 (88.2)
Incomplete ablation, number of lesions (%) 1 (2.5)
Time to diagnosis of incomplete ablation, months 3
Re-Ablation (IRE), n 1
Table 3. Results – Intervention. IRE irreversible electroporation.
Variable
Median LOS, days (range) 2 (2–14)
Number of patients with complications, n (%) 3 (12)
Dindo-Clavien classification
  Grade I 1
  Grade II 1
  Grad IIIa 1
Median duration of follow-up, months (range) 15 (2–32)
Local recurrence at ablation site, number of lesions (%) 4 (10)
  Time to diagnosis, months 3
  Re-Ablation, n 0
Overall disease progression, n (%) 17 (74)
  Intrahepatic only, n (%) 5 (29)
  Extrahepatic only, n (%) 4 (24)
  Intra- and Extrahepatic, n (%) 8 (47)
Deceased during follow-up, n (%) 7 (30)
Disease-free survival, median in months (range) 7 (0–26)
Overall survival, median in months (range) 18 (2–39)
Table 4. Post-interventional data. LOS Length of stay.
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Whether or not SMWA results in prolonged patient survival in the setting of stage IV cancer cannot be answered 
within this cohort.
Particularly in the setting of symptomatic hepatic NET metastases, SMWA offers a low-risk, tissue-sparing 
treatment option that can be repeated in case of tumor recurrence. At the moment, treatment with curative intent 
consists in liver resection, and has shown to improve survival9,10. Palliative therapeutic strategies for symptomatic 
disease also include surgical resection, sometimes as a debulking procedure. However, given the tendency for 
recurrence, a safe, minimally invasive solution is needed. Available data shows that RFA of NET liver metasta-
ses may be beneficial, but to this day, there is little evidence on the efficacy of SMWA of these lesions11. SMWA 
was performed in our patient series with stable disease, in symptomatic patients where systemic therapy was 
contra-indicated or when biopsy of a single lesion was needed for diagnostic purposes.
As for other, non-CRLM and non-NET liver metastasis, the benefit of resection remains unproven and there 
is currently few data on the oncological benefit of a local therapy for such patients10,27–32. Surgical resection might 
be beneficial in selected patients with well-controlled metastatic disease under systemic therapy, but with a signif-
icant morbidity27. In breast cancer for example, repeated histology becomes increasingly important for targeted 
therapy33. In this situation, adding local treatment to navigated biopsy of a liver metastasis is an interesting option.
conclusion
Percutaneous SMWA is a safe and technically feasible treatment for NCRLM, which can be repeatedly per-
formed in a low-risk minimally invasive setting and as an adjunct to systemic therapy, particularly if the lesion 
is unresectable or conventionally unablatable. SIMWA combines a precise biopsy (diagnostics), even for small, 
sub-centimetric lesions, with the actual ablation (treatment). Even in the increasingly important era of personal-
ized and patient-oriented medicine, the indication for SMWA must always be determined by a multidisciplinary 
tumorboard.
Clearly, further studies are needed to validate these results and to analyze the long-term oncological and qual-
ity of life benefit for these patients.
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